Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 643 matching trials from the live ClinicalTrials.gov search.
Conditions
Sjögren, Sjogren Disease, Sjogren's Syndrome
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Orlando, Florida • Brooklyn, New York • Memphis, Tennessee + 3 more
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Contact Lens Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Dry Eye Syndromes
Interventions
High concentration SI-614, Low concentration SI-614, Vehicle
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 7 more
Conditions
Dry Eye
Interventions
intense pulsed light
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Dry Eye Disease
Interventions
Vevye®, Xiidra®
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more
Conditions
Dry Eye
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast Ophthalmic, Systane Free, Lipiflow
Drug · Device
Lead sponsor
Tauber Eye Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Phase 4 Interventional Results available

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795
Conditions
Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solution
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Mild to Moderate Dry Eye Disease
Interventions
Restylane Defyne
Device
Lead sponsor
John C Meyer, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine, vehicle of OTX-101
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Rancho Cordova, California • Edgewood, Kentucky • New York, New York
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Bupivacaine Epiphora Trial

NCT03266081
Conditions
Epiphora, Ptosis
Interventions
0.75% bupivacaine
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Acute Comfort and Blur of Systane Ultra and Systane

NCT00748865
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

DOMPE -MT Neurotrophic Keratitis

NCT06947850
Conditions
Dry Eye, Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Meibomian Gland Dysfunction
Interventions
Tear Restore Mask
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Results available

e-Mobile Tablet for People With Chronic Conditions

NCT02833311
Conditions
Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions
Computer Tablet Group, Paper and Pencil Group, Contact Control Group
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 76 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
Interventions
Rinsada
Device
Lead sponsor
Rinsada
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Dry Eye Syndromes
Interventions
dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
SR Cornea Consultants
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sycamore, Illinois
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more